$1.48
3.90% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

C4 Therapeutics Inc Target price 2025 - Analyst rating & recommendation

C4 Therapeutics Inc Classifications & Recommendation:

Buy
50%
Hold
50%

C4 Therapeutics Inc Price Target

Target Price $13.75
Price $1.48
Potential
Number of Estimates 6
6 Analysts have issued a price target C4 Therapeutics Inc 2026 . The average C4 Therapeutics Inc target price is $13.75. This is higher than the current stock price. The highest price target is
$50.00 3,278.38%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 4 Analysts recommend C4 Therapeutics Inc to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the C4 Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the C4 Therapeutics Inc stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 35.58 22.71
71.39% 36.17%
EBITDA Margin -324.23% -563.64%
50.92% 83.51%
Net Margin -303.27% -527.60%
66.78% 73.97%

7 Analysts have issued a sales forecast C4 Therapeutics Inc 2025 . The average C4 Therapeutics Inc sales estimate is

$22.7m
Unlock
. This is
42.91% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$36.3m 8.75%
Unlock
, the lowest is
$7.0m 82.40%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $35.6m 71.39%
2025
$22.7m 36.17%
Unlock
2026
$21.7m 4.58%
Unlock
2027
$20.8m 4.10%
Unlock
2028
$207m 896.80%
Unlock
2029
$2.0b 887.62%
Unlock

3 Analysts have issued an C4 Therapeutics Inc EBITDA forecast 2025. The average C4 Therapeutics Inc EBITDA estimate is

$-128m
Unlock
. This is
17.79% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-114m 5.25%
Unlock
, the lowest is
$-143m 31.58%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-115m 15.89%
2025
$-128m 17.14%
Unlock
2026
$-149m 16.24%
Unlock
2027
$-177m 19.03%
Unlock

EBITDA Margin

2024 -324.23% 50.92%
2025
-563.64% 83.51%
Unlock
2026
-686.64% 21.82%
Unlock
2027
-852.30% 24.13%
Unlock

3 C4 Therapeutics Inc Analysts have issued a net profit forecast 2025. The average C4 Therapeutics Inc net profit estimate is

$-120m
Unlock
. This is
14.83% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-108m 3.40%
Unlock
, the lowest is
$-144m 37.68%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-108m 43.07%
2025
$-120m 11.05%
Unlock
2026
$-96.3m 19.63%
Unlock
2027
$-91.9m 4.54%
Unlock

Net Margin

2024 -303.27% 66.78%
2025
-527.60% 73.97%
Unlock
2026
-444.44% 15.76%
Unlock
2027
-442.40% 0.46%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.52 -1.69
43.07% 11.18%
P/E negative
EV/Sales negative

3 Analysts have issued a C4 Therapeutics Inc forecast for earnings per share. The average C4 Therapeutics Inc EPS is

$-1.69
Unlock
. This is
14.97% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.52 3.40%
Unlock
, the lowest is
$-2.02 37.41%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.52 43.07%
2025
$-1.69 11.18%
Unlock
2026
$-1.36 19.53%
Unlock
2027
$-1.30 4.41%
Unlock

P/E ratio

Current -1.00 58.16%
2025
-0.88 12.00%
Unlock
2026
-1.09 23.86%
Unlock
2027
-1.14 4.59%
Unlock

Based on analysts' sales estimates for 2025, the C4 Therapeutics Inc stock is valued at an EV/Sales of

-2.01
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -1.15 111.39%
2025
-2.01 74.70%
Unlock
2026
-2.11 4.80%
Unlock
2027
-2.20 4.28%
Unlock
2028
-0.22 89.97%
Unlock
2029
-0.02 89.88%
Unlock

P/S ratio

Current 2.64 86.45%
2025
4.63 75.15%
Unlock
2026
4.85 4.80%
Unlock
2027
5.06 4.28%
Unlock
2028
0.51 89.97%
Unlock
2029
0.05 89.87%
Unlock

Current C4 Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wells Fargo
Locked
Locked
Locked Dec 19 2024
Stephens & Co.
Locked
Locked
Locked Nov 18 2024
Analyst Rating Date
Locked
Wells Fargo:
Locked
Locked
Dec 19 2024
Locked
Stephens & Co.:
Locked
Locked
Nov 18 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today